Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of AGM and Posting of Annual Report

16th Nov 2026 07:00

RNS Number : 1178D
Tristel PLC
16 November 2026
 

 

Tristel plc

(“Tristel” or the “Company”)

 

Notice of Annual General Meeting and Posting of Annual Report

Directorate change

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the Notice of Annual General Meeting ("AGM") and the 2026 Annual Report and Accounts for the year ended 30 June 2026 will be posted to shareholders today and are available to download from the investor section of Company's website here.

 

The Company's AGM will take place on Thursday, 10 December 2026 at 11.00am at their offices at Unit 1b, Lynx Business Park, Fordham Road, Snailwell, Newmarket, Cambridgeshire CB8 7NY.

 

The Company also announces that after nine years on the Board, Tom Jenkins, Non-Executive Director, will not be standing for re-election at the forthcoming AGM, having reached the end of his tenure. He will step down from the Board at the conclusion of the meeting. The Board would like to express its sincere thanks to Tom for his dedication, support and valuable contribution to the Company and wish him well in the future. 

 

The Company intends to appoint a new independent Non-Executive Director in due course.

 

For further information please contact:

 

Tristel plc

Via Walbrook PR

Chris Lee, Chief Executive Officer

Anna Wasyl, Chief Financial Officer

https://investors.tristel.com/

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or [email protected]

Paul McManus / Anna Dunphy / Rachel Broad

Mob: 07980 541 893/ 07876 741 001 / 07747 515 393

 

 

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Callum Davidson / Joe Smith (Corporate Finance)

 

Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

 

 

 

About Tristel plc

 

Tristel plc is a global infection prevention company focused on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals with products under the Tristel brand, which also encompasses its sporicidal surface disinfection range offered as a sustainable alternative to commonly used pre-wetted plastic wipe.

 

Tristel’s head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 280 people across 16 subsidiaries selling into 40+ countries. The Company targets double digit revenue growth annually and an adjusted EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

 

The Company has been listed on the London Stock Exchange’s AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel’s product range please visit: https://tristel.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFFEFSDEMSELF

Related Shares:

Tristel
FTSE 100 Latest
Value10,881.55
Change-21.01